WINTON GROUP Ltd Takes Position in uniQure N.V. $QURE

WINTON GROUP Ltd acquired a new position in uniQure N.V. (NASDAQ:QURE) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 40,976 shares of the biotechnology company’s stock, valued at approximately $2,392,000. WINTON GROUP Ltd owned about 0.07% of uniQure at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Private Trust Co. NA acquired a new position in uniQure during the 3rd quarter valued at $28,000. Jones Financial Companies Lllp grew its position in uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 509 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of uniQure by 358.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock worth $99,000 after purchasing an additional 5,538 shares during the period. Knott David M Jr bought a new position in shares of uniQure during the 3rd quarter worth about $117,000. Finally, Teacher Retirement System of Texas acquired a new position in shares of uniQure during the second quarter valued at about $151,000. Institutional investors own 78.83% of the company’s stock.

uniQure Price Performance

NASDAQ:QURE opened at $18.26 on Wednesday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 10.43 and a current ratio of 10.43. The company has a 50-day moving average of $21.79 and a 200-day moving average of $29.66. uniQure N.V. has a 52 week low of $7.76 and a 52 week high of $71.50. The company has a market capitalization of $1.14 billion, a price-to-earnings ratio of -5.29 and a beta of 0.73.

uniQure (NASDAQ:QURE) last posted its earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.93) by $0.37. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. The business had revenue of $5.57 million for the quarter, compared to analysts’ expectations of $4.84 million. As a group, equities research analysts anticipate that uniQure N.V. will post -3.75 earnings per share for the current fiscal year.

Key Stories Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Multiple broker upgrades and higher price targets — Chardan raised its target and called for strong appreciation, RBC upgraded to Outperform with a $35 target, and Wells Fargo moved the stock to Overweight with a $60 target. These upgrades lift near-term sentiment and institutional interest. Chardan Capital Forecasts Strong Price Appreciation for uniQure (NASDAQ:QURE) Stock
• Positive Sentiment: Regulatory backdrop improved — market reacted positively after reports of a senior FDA biologics official (CBER director) leaving, which traders interpreted as reducing near-term regulatory friction for AMT‑130 and other gene‑therapy approvals. That narrative helped lift biotech names including QURE. UniQure shares surge 26% on US FDA shakeup even as momentum tumbles: Will new leadership greenlight Huntington’s therapy?
• Positive Sentiment: Analyst reaffirmations and buy ratings (HC Wainwright kept a $70 target) support upside expectations and may sustain buying interest around upcoming catalysts. uniQure: Regulatory Shift and AMT-130 Outlook Drive Reaffirmed Buy Rating and $70 Target
• Neutral Sentiment: High short interest (≈21.2% of float) increases volatility: it can amplify rallies (short-covering) or exacerbate declines if negative news hits. This is a key liquidity/volatility metric to monitor.
• Neutral Sentiment: Wall Street focus ahead of binary drug catalysts — several analyst notes highlight asymmetric upside tied to AMT‑130 and other programs, but outcomes remain binary and trial/regulatory risk is high. uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts
• Negative Sentiment: Multiple securities class action filings and law‑firm notices allege disclosures around AMT‑130 and related regulatory matters; several firms have issued investor alerts with an April 13 lead‑plaintiff deadline, creating legal overhang and potential liability risk. uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline
• Negative Sentiment: Regulatory accusations and investor‑rights firm claims — Hagens Berman and others highlight a public rebuke from federal health officials and allegations the company pushed “distorted” data for AMT‑130, which could materially damage credibility and regulatory prospects if substantiated. QURE ALERT: FDA Reportedly Accuses uniQure of Pushing “Distorted” and “Manipulated” Data For “Failed” AMT-130 Drug Amid Pending Securities Class Action – Hagens Berman

Insider Activity at uniQure

In other uniQure news, insider Jeannette Potts sold 3,412 shares of uniQure stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total transaction of $30,912.72. Following the sale, the insider directly owned 138,483 shares of the company’s stock, valued at approximately $1,254,655.98. The trade was a 2.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Matthew C. Kapusta sold 14,581 shares of the stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total value of $132,103.86. Following the completion of the transaction, the chief executive officer directly owned 660,658 shares of the company’s stock, valued at approximately $5,985,561.48. The trade was a 2.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 81,399 shares of company stock valued at $1,527,645. Corporate insiders own 4.79% of the company’s stock.

Analysts Set New Price Targets

QURE has been the subject of several research reports. The Goldman Sachs Group reduced their target price on shares of uniQure from $37.00 to $9.00 and set a “neutral” rating for the company in a research note on Tuesday, March 3rd. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $9.00 price target (down from $55.00) on shares of uniQure in a report on Monday, March 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of uniQure in a report on Wednesday, January 21st. Barclays assumed coverage on uniQure in a research report on Tuesday, January 27th. They issued an “equal weight” rating and a $31.00 price objective for the company. Finally, William Blair reissued a “market perform” rating on shares of uniQure in a report on Tuesday, November 11th. Nine analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $41.33.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.